Randomized Phase II Study Comparing Cabozantinib (NSC 761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

Trial Profile

Randomized Phase II Study Comparing Cabozantinib (NSC 761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Cabozantinib (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms CABOSUN
  • Most Recent Events

    • 16 Aug 2017 According to an Exelixis media release, based on the data from this study, Exelixis has submitted supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CABOMETYX (cabozantinib) tablets as a treatment for patients with previously untreated advanced renal cell carcinoma (RCC).
    • 02 Aug 2017 According to an Exelixis media release, data will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
    • 19 Jun 2017 According to an Exelixis media release, the company plan to submit the study results for presentation at an upcoming international medical meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top